Business Context and Reporting Period
Allogene Therapeutics, Inc. filed this Form 8-K on October 15, 2018, in connection with the closing of its initial public offering (IPO). The filing reports corporate governance amendments and the IPO closing; it does not provide a quarterly or annual operating update.
Key Financial and Capital Markets Metrics
- IPO shares sold: 20.7 million shares of common stock, including 2.7 million shares issued upon the underwriters’ full exercise of their option to purchase additional shares.
- Public offering price: $18.00 per share.
- Gross proceeds: Approximately $372.6 million, before underwriting discounts, commissions, and offering expenses.
- Revenue, profit, cash flow, margins, debt, and liquidity: The filing text does not provide clear values or updated information for these metrics.
Material Changes and Corporate Actions
- The company filed an amended and restated certificate of incorporation with the Delaware Secretary of State, effective in connection with the IPO closing.
- The company adopted amended and restated bylaws effective October 15, 2018, also in connection with the IPO.
- The amendments had been approved previously by the board on September 26, 2018, and by stockholders on October 1, 2018.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance, management outlook, operating forecast, or specific risk update. The principal unusual item is the company’s IPO and associated capital raise. Net proceeds are not stated because underwriting discounts, commissions, and offering expenses had not been deducted from the disclosed gross proceeds.
Important Facts for Investors to Verify
- Confirm the final net IPO proceeds after underwriting discounts, commissions, and offering expenses.
- Review the amended and restated certificate of incorporation and bylaws filed as Exhibits 3.1 and 3.2.
- Assess how the IPO proceeds affect the company’s cash runway, research and development plans, and future financing needs using subsequent filings.
- Review subsequent periodic filings for operating results, liquidity, debt, clinical development progress, and material risks not addressed in this 8-K.